QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein,...

Core News & Articles

- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation's Most Trusted Health Care Distributo...

 henry-schein-sees-steady-smile-as-dental-market-growth-holds-analyst

Henry Schein sees steady dental market trends, with Piper Sandler expecting stronger equipment growth in the second half of 2025.

 barrington-research-maintains-outperform-on-henry-schein-maintains-78-price-target

Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:HSIC) with a Outperform and maintains $78 price t...

 henry-schein-authorizes-750m-share-repurchase-plan

Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care products and services to office-based dental ...

 evercore-isi-group-upgrades-henry-schein-to-outperform-announces-83-price-target

Evercore ISI Group analyst Elizabeth Anderson upgrades Henry Schein (NASDAQ:HSIC) from In-Line to Outperform and announces $...

 oral-genome-partners-with-henry-schein-to-expand-saliva-based-diagnostics-nationwide

Oral Genome, a leading innovator in salivary testing, today announced a strategic partnership with Henry Schein, the world'...

 jp-morgan-maintains-overweight-on-henry-schein-lowers-price-target-to-76

JP Morgan analyst Rachel Vatnsdal maintains Henry Schein (NASDAQ:HSIC) with a Overweight and lowers the price target from $8...

 ubs-maintains-neutral-on-henry-schein-lowers-price-target-to-70

UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and lowers the price target from $75 to $70.

 evercore-isi-group-maintains-in-line-on-henry-schein-lowers-price-target-to-70

Evercore ISI Group analyst Ross Muken maintains Henry Schein (NASDAQ:HSIC) with a In-Line and lowers the price target from $...

 henry-scheins-2025-outlook-hinges-on-strong-second-half-execution

Henry Schein Inc. stock down on Q2 earnings, misses EPS but beats sales. Total net sales up 3.3%, $23M in restructuring costs. ...

 henry-schein-affirms-fy2025-adj-eps-guidance-of-480-494-vs-488-est-affirms-fy2025-sales-guidance-of-12425b-13180b-vs-12956b-est

Henry Schein (NASDAQ:HSIC) affirms FY2025 Adj EPS guidance from $4.80-$4.94 to $4.80-$4.94 vs $4.88 analyst estimate. Affirms F...

 henry-schein-q2-adj-eps-110-misses-120-estimate-sales-3240b-beat-3222b-estimate

Henry Schein (NASDAQ:HSIC) reported quarterly earnings of $1.10 per share which missed the analyst consensus estimate of $1.20 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION